Anti-PD-1 (Toripalimab), Humanized Antibody

Anti-PD-1 (Toripalimab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a humanized IgG4 recombinant monoclonal antibody that binds to programmed death receptor-1 (PD-1) and prevents the interaction with its ligands PD-L1 and PD-L2. This results in the activation of T-cell mediated immune response and inhibits tumor cell growth. The original drug received approval in China in 2018 as the second line of treatment for melanoma. Currently, the drug is evaluated for efficacy and toxicity in Phase I-III clinical trials for nasopharyngeal carcinoma, head and neck squamous cell carcinoma and gastric adenocarcinoma

Immunogen Sequence:Human PD-1

Target Alternative Name:JS001, Tab001, PD1, PDCD1, CD279, SLEB2, hPD-1, hPD-l, hSLE1

Species Reactivities:Human

Tag Line:The biosimilar is a humanized monoclonal antibody that binds to PD-1 and prevents the association with its ligands PD-L1 and PD-L2, thus activating T-cell mediated immune response and inhibiting tumor growth

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.